RACHEL TIU: Open Payments
NPI 1780268979 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,886 in 93 payments from 12 companies in 2025. Trend: 2023 $2,553 · 2024 $2,223 · 2025 $1,886
Food & beverage: $1,886
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $545 |
| Amgen Inc. | 25 | $347 |
| UCB, Inc. | 9 | $291 |
| PFIZER INC. | 10 | $165 |
| GlaxoSmithKline, LLC. | 8 | $152 |
| Genentech USA, Inc. | 4 | $97 |
| Novartis Pharmaceuticals Corporation | 4 | $84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $61 |
| GENZYME CORPORATION | 1 | $33 |
Products named: RINVOQ, Bimzelx, BENLYSTA, XELJANZ, SKYRIZI, KRYSTEXXA, TAVNEOS, ENBREL.
Industry payments across TX — which companies pay providers there.
